Navigation Links
Biodel Inc. to Present at the 2008 Citi Investment Research Global Healthcare Conference on May 22nd 2008
Date:5/14/2008

DANBURY, Conn., May 14 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Gerard Michel, Chief Financial Officer, Vice President of Corporate Development and Treasurer of Biodel, will present a corporate update at the 2008 Citi Investment Research Global Healthcare Conference on Thursday, May 22, 2008 at 1:00 p.m. Eastern Time. The conference will be held at the New York Hilton in New York, New York.

Interested parties may access a link to a live webcast of the corporate presentation in the investor relations section of Biodel's website at http://www.biodel.com. An archive of the presentation will be available at the same location.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biodel Inc. Added to NASDAQ Biotechnology Index
2. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
3. Biodel Inc. to Present at the Bank of America 2008 Health Care Conference on May 13th 2008
4. Biodel Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference April 30th 2008
5. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
6. Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results
7. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
8. Biodel Inc. Announces Pricing of Public Offering
9. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
10. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
11. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Supportive materials will help regenerate heart tissue 2UAB bone center director wins distinguished service award from clinical pathology society 2Why King Kong failed to impress 2SleepApneaUSA net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB 26apos 3Bs Sleep Apnea Testing Recommendations 60813 1SleepApneaUSA net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB 26apos 3Bs Sleep Apnea Testing Recommendations 60813 2SleepApneaUSA net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB 26apos 3Bs Sleep Apnea Testing Recommendations 60813 3SleepApneaUSA net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB 26apos 3Bs Sleep Apnea Testing Recommendations 60813 4SleepApneaUSA net Announced An Immediate Alternative Sleep Apnea Solution In Response To The NTSB 26apos 3Bs Sleep Apnea Testing Recommendations 60813 5Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections 28ABSSSI 29 6040 1Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections 28ABSSSI 29 6040 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections 28ABSSSI 29 6040 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections 28ABSSSI 29 6040 4Clothing Choices Present Barrier to Outdoor Activity for Kids in Child Care Centers 60807 1Clothing Choices Present Barrier to Outdoor Activity for Kids in Child Care Centers 60807 2Clothing Choices Present Barrier to Outdoor Activity for Kids in Child Care Centers 60807 3